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Post-traumatic stress disorder (PTSD) is reported in some studies to be associated 
with increased glucocorticoid (GC) sensitivity. Two common glucocorticoid receptor 
(GR) polymorphisms (N363S and BclI) appear to contribute to the population 
variance in GC sensitivity. There is some evidence that there may be a genetic 
predisposition to PTSD. Hence we studied 118 Vietnam war veterans with PTSD for 
(i) GR polymorphisms, particularly the N363S and the BclI polymorphisms which are 
thought to be GC sensitising, and (ii) two measures of GC sensitivity, the low-dose 
0.25 mg dexamethasone suppression test (LD-DST) and the dermal vasoconstrictor 
assay (DVVA). The DST and GR polymorphisms were also performed in 42 combat 
exposed Vietnam war veterans without PTSD. 
 
Basal plasma cortisol levels were not significantly different in PTSD (399.5±19.2 
nmol/L, N=75) and controls (348.6±23.0 nmol/L, N=33) and the LD-DST resulted in 
similar cortisol suppression in both groups (45.6±3.2 vs. 40.8±4.1%). The cortisol 
suppression in PTSD patients does not correlate with Clinician Administered PTSD 
Scores (CAPS), however there was a significant association between the BclI GG 
genotype and low basal cortisol levels in PTSD (P=0.048). The response to the 
DVVA was similar to controls (945±122, N=106 vs. 730±236, N=28, P=0.42). PTSD 
patients with the GG genotype, however, tended to be more responsive to DVVA and 
in this group the DVVA correlated with higher CAPS scores. The only exon 2 GR 
polymorphisms detected were the R23K and N363S. Heterozygosity for the N363S 
variant in PTSD, at 5.1% was not more prevalent than in other population studies of 
the N363S polymorphism in Caucasians (6.0–14.8%). The GG genotype of the BclI 
polymorphism found to be associated with increased GC sensitivity in many studies 
showed a tendency towards increased response with DVVA and correlated with 
higher CAPS scores. 
 
In conclusion, the N363S and BclI GR polymorphisms were not more frequent in 
PTSD patients than controls and reported population frequencies. Our PTSD group 
did not display GC hypersensitivity, as measured by the LD-DST and DVVA. In a 
subset of PTSD patients with the BclI GG genotype, CAPS scores and basal cortisol 
levels were negatively correlated.  
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1. Introduction 
Post-traumatic stress disorder (PTSD) is a disabling syndrome that affects many 
combat exposed Vietnam war veterans. It appears to develop in biological 
predisposed individuals after exposure to life threatening stress. The stress system in 
PTSD patients is chronically dysregulated, characterized by a heightened reactivity of 
the sympathetic nervous system (Pitman et al., 1990) and alterations in the 
hypothalamic–pituitary–adrenal (HPA) axis resulting in relative hypocortisolism 
(Yehuda et al., 1990, Yehuda et al., 1995 and Boscarino, 1996). Enhanced sensitivity 
to feedback inhibition by glucocorticoids (GC) could account for the low cortisol 
levels and several investigators have found that, in PTSD patients, cortisol levels fall 
excessively (‘hypersuppressible’) after low-dose dexamethasone (DEX) (Yehuda et 
al., 1995 and Stein et al., 1997). Further evidence for increased GC sensitivity in 
PTSD comes from the findings of a blunted adrenocorticotropic hormone (ACTH) 
response to corticotrophin-releasing factor (CRF) in PTSD (Smith et al., 1989) and an 
exaggerated ACTH response to metyrapone in PTSD compared to normal subjects 
(Yehuda et al., 1996). 
 
Evidence for a genetic predisposition to PTSD comes from results in twin studies of 
Vietnam war veterans where it was found that genetic factors accounted for up to 30% 
of variability in PTSD symptoms and monozygotic twins were more highly 
concordant for combat exposure than dizygotic twins (True et al., 1993). It has also 
been noted that there is a trend for increased GC sensitivity in unaffected first degree 
relatives of PTSD patients (Yehuda et al., 2002). 
 
Recent studies have found a glucocorticoid receptor (GR) polymorphism in exon 2 
(N363S) which alters the N-terminal transactivation domain to be associated with GC 
hypersensitivity, increased body mass index (BMI) and low bone mineral density 
(Huizenga et al., 1998a, Huizenga et al., 1998b and Lin et al., 1999). In addition, the 
BclI polymorphism located in intron 2, has been associated with high blood pressure, 
insulin sensitivity, body mass index and abdominal fat distribution (Weaver et al., 
1992 and Buemann et al., 1997) as well as increased GC sensitivity, determined by 
the skin blanching response to topical GCs and increased cortisol suppression after 
low-dose DEX (Panarelli et al., 1998 and van Rossum et al., 2002). 
 
The acute cortisol response to a standardized psychosocial stressor was enhanced in 
10 N363S carriers and diminished in 18 BclI GG carriers compared to controls, 
suggesting that these common GR polymorphisms may alter real-life stress responses 
(Wust et al., 2004). 
 
We therefore hypothesised that the mechanism of central GC hypersensitivity 
observed in PTSD might involve altered GR function, due to inherited 
polymorphisms, leading to increased receptor sensitivity. We determined the 
genotypes for the GR polymorphisms N363S and BclI in Vietnam veterans with 
PTSD and combat exposed controls and then examined the relationship between the 
genotypes and measures of central (hypothalamic–pituitary unit) and peripheral 
(microvasculature) GC sensitivity as assessed by low-dose DEX suppression test 
(DST) and the dermal vessel vasoconstrictor assay (DVVA). 
 
2. Materials and methods 
2.1. Subjects 
One hundred and eighteen combat exposed Vietnam veterans (mean age±SD; 
55.7±4.2; 42–68 yr) were recruited from a nationally accredited inpatient and 
outpatient PTSD treatment program conducted at the Keith Payne Unit, Greenslopes 
Private Hospital, Brisbane, Australia. Diagnosis of PTSD was made using the 
Clinician Administered PTSD Scale (CAPS) for DSM-IV (current diagnostic version) 
and psychiatric interview. The mean CAPS score obtained for this group was 
79.4±14.4 (SD) with a range of 36–109 (maximum possible score=136). Patients 
diagnosed with other active psychiatric disorders were excluded from the program. 
Patients abstained from substance abuse during the program, however, medication 
was not ceased. Psychotropic medications do not influence the molecular studies but 
might affect neuroendocrine tests; however, previous studies have indicated little 
effect from the commonly employed selective serotonin re-uptake inhibitors (SSRIs) 
(Torpy et al., 1997). 
 
Combat exposed non-PTSD volunteers were recruited by newspaper advertisement 
and through the co-operation of Vietnam veterans' regiment associations. Forty-two 
subjects (mean age±SD; 61.2±7.1; 53–76 yr) were recruited. They were interviewed 
for general medical history and health status was assessed with routine blood tests. 
Features of metabolic syndrome (diabetes, hypertension, central adiposity and 
hyperlipidaemia) were noted. Exclusion of PTSD and other psychiatric disorders was 
determined by CAPS and clinical interview. A CAPS score range of 0–28 (mean±SD; 
8.5±7.9) was obtained for this group. The study was approved by the Greenslopes 
Private Hospital and University of Queensland Human Ethics Committees and written 
informed consent was obtained from all subjects. 
 
2.2. Study protocol 
On day 1 between 1500 and 1700 h a skin patch for the DVVA was applied and 
removed the following morning at 0800 h for reading. After an overnight fast blood 
was collected on day 3 from an antecubital vein for DNA and basal cortisol levels. 
After taking DEX at 2300 h on day 3, and a post-DEX blood sample was collected at 
0800 h on day 4. 
 
2.3. Dermal vessel vasoconstrictor assay (DVVA) 
The dermal vessel vasoconstrictor assay (DVVA) was used as it is one of the few 
reported in vivo tests of peripheral GC sensitivity. DVVA responses have also been 
shown to vary in relation with the BclI GR polymorphism (Panarelli et al., 1998). 
Solutions of beclomethasone dipropionate (Sigma-Aldrich Pty Ltd, Castle Hill, NSW, 
Australia) were prepared in propylene glycol/water/ethanol (49:49:2, vol/vol) at 
concentrations of 0, 5, 10, 50 and 100 ug/mL. A template containing five circles to 
accommodate 18 mm diameter WhatmanR filter paper (Whatman International Ltd, 
Maidstone, England) was fixed on the volar aspect of the non-dominant forearm. 
Between 1500 and 1700 h a pre-test erythema index was measured at each site by 
reflectance spectrophotometry (Erythemameter, Diastron, UK). The beclomethasone 
solutions (50 µL) were then applied to five separate filter papers in random order and 
covered with a waterproof transparent Tegaderm™ dressing (3M Health Care, St 
Paul, MN). The dressing was removed the following morning at 08:00 h and the 
blanching response measured as a decrease in erythema index. A corrected erythema 
index response was calculated by subtracting the pre-test difference between each 
concentration site and the zero beclomethasone site from the comparable difference 
measured on the day following application of the steroid. This corrects for forearm 
site differences due to variation in blood flow and variations with time. From these 
delta values area under the curve (AUC) estimations were calculated for each subject 
over the full range of steroid concentrations using the trapezoidal rule. A small 
number of tests were excluded from analysis due to a complete lack of blanching 
response or an extreme erythematous reaction on Tegaderm removal. Subjects using 
systemic or topical GCs were also excluded from test. 
 
2.4. Low-dose DST 
Initial studies with 0.5 mg DEX produced complete cortisol suppression (<25 
mmol/L) in controls so the 0.25 mg dose was used as described in a previous report of 
PTSD patients (Yehuda et al., 1995). After an overnight fast subjects had venous 
blood collected into EDTA-containing tubes at 08:00 h for plasma cortisol 
measurement. Subjects were given 0.25 mg DEX (half a 0.5 mg tablet of DEX) and 
instructed to ingest it at 2300 h that evening. The following morning a post-DEX 
blood sample was collected at 0800 h. Pre- and post-DEX plasma cortisol 
concentrations were determined by RIA (Diagnostic Systems Laboratories Inc., 
Webster, TX). Intra- and inter-assay variations of the assay were 6.1 and 8.0%, 
respectively, and the cortisol sensitivity was 3 nmol/L. Subjects diagnosed with 
diabetes were excluded from this test. 
 
2.5. Genetic studies 
Amplification of the GR exon 2. Genomic DNA was extracted from peripheral blood 
leukocytes using a commercial method (Nucleon BACC2, Amersham Biosciences Pty 
Ltd, Baulkham Hills, NSW, Australia). Exon 2 of the GR was amplified by PCR 
using 1 µg of genomic DNA in a reaction volume of 100 µL containing sterile ultra-
pure water, 10× buffer, 3 mM MgCl2, 2 U Taq DNA polymerase (Qiagen Pty Ltd, 
Clifton, Vic., Australia), 200 µM each of dNTPs and 300 nM each of specific exon 2 
GR primers 5′-TCG GAT CAG GAA GAT AAT GTG A-3′ (forward) and 5′-CAA 
AAG GCC ACT TAA ACT TAT TCA-3′ (reverse). The PCR conditions used were 
one cycle of denaturation at 95 °C for 5 min, followed by 30 cycles of denaturation at 
94 °C for 1 min, annealing at 55 °C for 1.5 min, extension at 72 °C for 1.5 min and a 
final cycle at 72 °C for 5 min. The PCR product (1404 bp) was purified for 
sequencing using the NucleoSpinR Extract kit (Macherey-Nagel, Duren, Germany). 
 
Exon 2 GR polymorphisms. GR polymorphisms were detected by automated direct 
sequencing using an ABI 377 DNA sequencer (PE Applied Biosystems, Foster, CA) 
and a dideoxy cycle sequencing protocol in the presence of specific primers and 
fluorescent labelled dideoxy terminators (Sanger et al., 1977). To ensure accuracy of 
mutation detection in exon 2 of the GR four overlapping sequence reactions were 
employed. In addition to the GR PCR primers the following sequencing primers were 
used: 5′-CGG TAA AAT GAG AGG CTT GC-3′ and 5′-GGC GGG AGA AGA CGA 
TTC-3′. 
 
Genotyping of GR BclI RFLP. Intron 2 primers were designed for a PCR product 
(335 bp) to include the BclI RFLP C to G mutation 646 bp downstream of exon 2. 
PCR was performed using 0.5 µg genomic DNA in a 50 µL reaction containing sterile 
water, PCR buffer (10×), Q-solution (5×), 1 U Taq DNA polymerase (Qiagen), 200 
uM each of dNTPs and 300 nM each of the following primers 5′-TGC TGC CTT 
ATT TGT AAA TTC GT-3′ (forward) and 5′-AAG CTT AAC AAT TTT GGC CAT 
C-3′. The PCR conditions used were the same as those employed for the GR PCR. 
The genotypes were determined by BclI digestion (15 U) for 1.5 h at 50 °C and 
subsequent separation on 2% agarose gels. The CC genotype produced two bands 
(221 and 117 bp), the CG genotype three bands and the GG genotype remained 




Figure 1. Results of a BclI restriction enzyme digest of a 335 bp PCR product from intron 2 of the GR. 
This DNA product contains a C to G mutation 646 nucleotides downstream from exon 2. Lane 1 shows 
a DNA ladder with as 100 bp interval. Lanes 2, 4 and 6 show undigested product, lane 3 the two bands 
(117 and 222 bp) of the CC homozygote, lane 5 the three bands (117, 222 and 335 bp) of the CG 
heterozygote and lane 7 the undigested GG homozygote 
 
2.6. Statistical analyses 
All descriptive statistics and analyses were performed using the Statistica computer 
application (Statsoft, Tulsa, OK). Differences in measures of baseline cortisol and 
responses to low-dose DST between PTSD and controls were compared with two-
tailed, unpaired t-tests. Correlations between CAPS and various parameters were 
measured using the Pearson product–moment correlation coefficient. The AUC for 
erythema index from the DVVA was calculated by the trapezoidal method and 
differences in genotypes between the study groups were analysed with two-tailed, 
unpaired t-tests. Allelic frequencies for GR polymorphisms in PTSD and controls 
were compared by computing a R by C table chi-square statistic. All results are 
expressed as mean±SE, unless otherwise indicated as standard deviation (SD). P 
values ≤0.05 were considered to be significant. 
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Post-traumatic stress disorder (PTSD) is reported in some studies to be associated 
with increased glucocorticoid (GC) sensitivity. Two common glucocorticoid receptor 
(GR) polymorphisms (N363S and BclI) appear to contribute to the population 
variance in GC sensitivity. There is some evidence that there may be a genetic 
predisposition to PTSD. Hence we studied 118 Vietnam war veterans with PTSD for 
(i) GR polymorphisms, particularly the N363S and the BclI polymorphisms which are 
thought to be GC sensitising, and (ii) two measures of GC sensitivity, the low-dose 
0.25 mg dexamethasone suppression test (LD-DST) and the dermal vasoconstrictor 
assay (DVVA). The DST and GR polymorphisms were also performed in 42 combat 
exposed Vietnam war veterans without PTSD. 
 
Basal plasma cortisol levels were not significantly different in PTSD (399.5±19.2 
nmol/L, N=75) and controls (348.6±23.0 nmol/L, N=33) and the LD-DST resulted in 
similar cortisol suppression in both groups (45.6±3.2 vs. 40.8±4.1%). The cortisol 
suppression in PTSD patients does not correlate with Clinician Administered PTSD 
Scores (CAPS), however there was a significant association between the BclI GG 
genotype and low basal cortisol levels in PTSD (P=0.048). The response to the 
DVVA was similar to controls (945±122, N=106 vs. 730±236, N=28, P=0.42). PTSD 
patients with the GG genotype, however, tended to be more responsive to DVVA and 
in this group the DVVA correlated with higher CAPS scores. The only exon 2 GR 
polymorphisms detected were the R23K and N363S. Heterozygosity for the N363S 
variant in PTSD, at 5.1% was not more prevalent than in other population studies of 
the N363S polymorphism in Caucasians (6.0–14.8%). The GG genotype of the BclI 
polymorphism found to be associated with increased GC sensitivity in many studies 
showed a tendency towards increased response with DVVA and correlated with 
higher CAPS scores. 
 
In conclusion, the N363S and BclI GR polymorphisms were not more frequent in 
PTSD patients than controls and reported population frequencies. Our PTSD group 
did not display GC hypersensitivity, as measured by the LD-DST and DVVA. In a 
subset of PTSD patients with the BclI GG genotype, CAPS scores and basal cortisol 
levels were negatively correlated.  
 
3.1. GR polymorphisms 
Sequence analyses of the GR exon 2 were performed in 118 PTSD and 42 control 
subjects. Allelic frequencies for PTSD and controls for previously reported mutations 
(5 missense and 2 silent polymorphisms) are shown in Table 1. N363S polymorphism 
carriers were detected at a rate of 5.1% in PTSD compared to 2.4% in controls 
(χ2=0.54, P=0.46). Similarly the R23K polymorphism was found only in 
heterozygous form and occurred in linkage disequilibrium with a silent nucleotide 
substitution in codon 22 (Koper et al., 1997). The R23K carrier frequency in PTSD 
was not significantly different to that in controls (5.1 vs 9.5%, χ2=1.04, P=0.31). No 
additional mutations in exon 2 were detected and the variants F29L, L112F and 
D233N first reported in puerperal psychosis and schizophrenia (Feng et al., 2000) 
were not identified in our study populations. The GR genotypes (CC, CG and GG) 
resulting from the BclI polymorphism were determined in 118 PTSD and 42 control 
subjects. The genotype frequencies for both PTSD (CC, 0.47; CG, 0.42; GG, 0.11) 
and controls (CC, 0.36; CG, 0.48; GG, 0.16) were consistent with the Hardy-
Weinberg equilibrium and the genotype distributions were not significantly different 








3.2. Low-dose DST and GR polymorphisms 
The morning fasting baseline cortisol concentrations in PTSD and controls were not 
significantly different (Table 2, 399.5±19.2 nmol/L, N=75 vs. 348.6±23.0 nmol/L, 
N=33) and over 50% of measurements were below 400 nmol/L in both groups. The ∆ 
cortisol response to low dose DEX (0.25 mg) was not significantly different to 
controls (Table 2, 192.8±16.9 vs. 146.0±17.8 nmol/L). A comparable range of % 
cortisol suppression was observed in PTSD (−26.0 to 92.3%) compared to controls 
(−33.6 to 83.1%). The difference between the number of hyper-suppressors, that is, 
subjects suppressing cortisol below 140 nmol/L observed in PTSD (37.3%) and 
controls (27.3%) was not significant (χ2=1.03, P=0.31). For the PTSD group no 
significant correlations were found between CAPS scores, basal and post-DEX 

















Table 3 shows cortisol levels in PTSD before and after administration of 0.25 mg 
DEX for the N363S alleles and the BclI genotypes, respectively. For both 
polymorphisms there was no difference in baseline cortisol levels. However, CAPS 
scores tended to be greater for the GG genotype compared to CC and CG (84.3 vs. 
79.6 and 78.7) and a significant negative correlation was found between CAPS and 
basal cortisol levels for the GG genotype (r=−0.71, P=0.048). The mean decrease in 
cortisol for the N363S carrier was not significantly different from that observed in the 
non-N363 carrier (68.6±86.2 vs. 199.8±17.0 nmol/L). Similarly no significant 
difference in ∆ cortisol levels between the CC (196.9±30.2 nmol/L), CG (188.7±23.6 
nmol/L) and GG (195.0±31.0 nmol/L) BclI genotypes was found in PTSD. 
 
3.3. DVVA and GR polymorphisms 
The blanching response of the forearm vasculature to topical beclomethasone as 
measured by a decrease in erythema index (an increased AUC) was not significantly 
different in PTSD than in controls (945±122 vs 730±236, P=0.42). N363 allelic status 
did not alter the response to DVVA in the PTSD group (Table 3). In PTSD the BclI 
GG genotype (1400±300) was not significantly different to beclomethasone than the 
CC (873±169) and CG (901±206) genotypes (Table 3). The GG genotype did not 













This is the first study examining the possibility that PTSD may be associated with 
altered frequencies of GR polymorphisms. We did not find altered frequencies of 
common GR polymorphisms in PTSD. In addition, the measures of GC sensitivity in 
our PTSD patients, the LD-DST and the DVVA test, were normal, in contrast to 
expectation based on other reports (Yehuda, 1997). A subgroup of PTSD patients with 
the BclI GG genotype tended to be more responsive to DVVA and have higher 
Clinician Administered PTSD Scale (CAPS) scores that were significantly negatively 
correlated with basal plasma cortisol levels. However, the BclI GG genotype group 
was small and this finding needs verification in a different patient group. 
 
Lower urinary and plasma cortisol levels in PTSD compared to controls have been 
documented but a number of studies have not shown this difference (Yehuda, 2002). 
In this study baseline plasma cortisol levels in 75 subjects with PTSD and 33 controls 
were similar (399.5±19.2 vs 348.6±23.0 nmol/L) and comparable with mean values 
(range 127–596 nmol/L) obtained from other PTSD studies (Yehuda, 2002). Single 
plasma measurements are not regarded as the most reliable estimates of cortisol 
because of some variability caused by transient stressors, however this is unlikely to 
be responsible for the above finding as all samples were collected under carefully 
controlled fasting conditions. 
 
In this study an increased sensitivity to DEX in PTSD was not found. We observed 
similar levels of cortisol suppression to 0.25 mg DEX in PTSD (45.6±3.2%) and to 
controls (40.8±4.5%); the percentage of hyper-responders (suppression <140 nmol/L) 
also did not differ significantly. We found that the 0.25 mg DEX dose was more 
sensitive in distinguishing hyper-responders compared to 0.5 mg DEX used in our 
initial studies where most subjects suppressed by greater than 80% (results not 
shown). Enhanced suppression of cortisol in trauma survivors with PTSD compared 
to non-exposed subjects has been documented in a number of studies after 
administration of both 0.25 and 0.5 mg DEX (Yehuda et al., 1995, Stein et al., 1997 
and Yehuda et al., 2002). However, in another study on adolescent earthquake victims 
enhanced suppression to DEX was observed at 4 pm in the group with more severe 
PTSD symptoms who had been closer to the epicentre compared to those further from 
the epicentre (Goenjian et al., 1996). The degree of suppression for these two groups 
was similar at 8 am. This finding suggests that the DEX suppression may be 
prolonged in PTSD. In a comparable study to ours using 0.25 mg DEX (Yehuda et al., 
1995) the level of cortisol suppression in combat veterans with PTSD was higher than 
that observed in our combat veterans (54.4 vs 45.6%) and lower (36.7 vs 40.8%) for 
combat veterans without PTSD. The results observed in our study may be a reflection 
on the different modes of recruitment of the two groups. The controls were generally 
an older group who might have had a reduced metabolic clearance of DEX compared 
to PTSD veterans resulting in relatively greater suppression. This was not confirmed 
in this study as circulating DEX levels were not measured. However in a study on the 
variability and sensitivity of a low-dose DST in an elderly population the relationship 
between pre- and post-DEX cortisol concentrations was found to be strongly 
associated with the actual DEX levels (Huizenga et al., 1998a and Huizenga et al., 
1998b). Even though the DST has been fairly ubiquitously applied to evaluate GC 
feedback sensitivity some reservations about its validity have been expressed. These 
concerns relate to the different affinities of DEX and cortisol for GR subtypes (de 
Kloet, 1991) and the level of the HPA axis at which inhibition is recognised being 
primarily at the pituitary for DEX as it does penetrate well into the brain (Miller et al., 
1992). 
 
There is some evidence that variability in GC sensitivity is tissue-specific and not a 
trait affecting all tissues equally (Ebrecht et al., 2000). Hence, we performed a central 
measure of GC sensitivity (DST), and a peripheral assessment of GC sensitivity 
(DVVA). As a measure of GC-induced dermal vasoconstriction the resultant skin 
blanching has proved useful in assessing GC potency and sensitivity. Using this 
methodology patients with essential hypertension have been shown to exhibit 
increased skin blanching compared to normotensive subjects (Walker et al., 1996) and 
in another study it was found that the intensity of blanching correlated with the 
therapeutic sensitivity to GCs in asthma (Brown et al., 1991). We did not find a 
significant difference in the DVVA response between veterans with PTSD and the 
control group even though the overall response to topical beclomethasone was greater 
in PTSD. Consistent with the notion that considerable variation in GC sensitivity 
exists across individuals we observed a wide range of inter-individual responses to 
DVVA in both groups. 
 
A number of mutations in the GR have been identified that show associations with 
GC sensitivity (Huizenga et al., 1998a, Huizenga et al., 1998b, Panarelli et al., 1998 
and van Rossum et al., 2002). In particular the N363S and the BclI polymorphisms 
were investigated to see whether these mutations might predispose to an increased GC 
sensitivity observed in some PTSD subjects. To determine the frequency of these GR 
mutations, exon 2 containing the N-terminal domain involved in modulating 
transcriptional activation was sequenced. The only polymorphisms detected were the 
R23K linked to phenotypes ranging from asymptomatic to GC resistant (Koper et al., 
1997) and the N363S carrier associated with GC hypersensitivity (Huizenga et al., 
1998a and Huizenga et al., 1998b). In our groups we did not detect the F29L, L112F 
and D233N variants first described in study on patients diagnosed with puerperal 
psychosis and schizophrenia (Feng et al., 2000) or any other new mutations. The 
allelic frequencies of these polymorphisms were not significantly different between 
the PTSD and control groups and we did not find an enhanced presence of the N363S 
carrier genotype in PTSD (5.1%) compared to those observed (6–9.6%) in other 
studies (Huizenga et al., 1998a, Huizenga et al., 1998b, Lin et al., 1999, Dobson et al., 
2001 and Rosmond et al., 2001). Using two measures of GC sensitivity (low-dose 
DST and DVVA) no significant associations between N363S carrier status and 
increased sensitivity to GCs were found in the PTSD group. It is difficult to interpret 
the results of the control group as only one N363S carrier was detected. In the 
literature there are mixed findings linking this asparagine to serine point mutation to 
increased GC sensitivity. Studies in an elderly Dutch population found the N363S was 
associated with enhanced suppression of cortisol to DEX, increased BMI and a 
lowered bone mineral density in the lumbar spine (Huizenga et al., 1998a and 
Huizenga et al., 1998b). Similarly in British (Dobson et al., 2001) and Australian 
studies (Lin et al., 1999) significant associations between the N363S polymorphism 
and greater waist–hip ratio in males and obesity (BMI>25), respectively. In contrast 
other studies in Danish (Echwald et al., 2001) and Swedish men (Rosmond et al., 
2001) did not find any association between the N363S mutation, obesity, and the 
degree of cortisol suppression with DEX. The different genetic backgrounds and/or 
the gender composition of the populations studied could have contributed to these 
disparate findings. These variable results therefore make it difficult to conclude 
whether the N363S GR polymorphism is a reliable genetic marker of GC sensitivity. 
The exact molecular mechanism of how the N363S variant might cause increased GC 
sensitivity is not known; however, it is proposed that new serine residue allows for 
modulation of the phosphorylation state of the receptor and thereby altering protein 
interactions with transcription factors. Even though there is good evidence of 
increased GC sensitivity in the N363S from a number of in vivo studies, in vitro 
studies on the N363S polymorphism found no effects on its ability to bind hormone or 
activate transcription (Gaitan et al., 1995 and de Lange et al., 1997). 
 
The BclI polymorphism in the GR previously characterised as the large (4.5 kb) and 
small (2.3 kb) restriction fragments has recently been identified as a C to G mutation 
in intron 2, 646 nucleotides downstream from exon 2 (van Rossum et al., 2002). A 
number of investigations have found associations between the large allele (4.5 kb) or 
the GG genotype and parameters indicative of increased GC sensitivity such as 
increased abdominal visceral fat (Buemann et al., 1997), hyperinsulinaemia (Weaver 
et al., 1992), body mass index (van Rossum et al., 2002) and evidence for increased 
sensitivity to topical budesonide (Panarelli et al., 1998) and increased sensitivity of 
the HPA negative feedback axis (van Rossum et al., 2002). In this study the BclI 
allelic frequencies for PTSD and controls (C=0.68 and 0.60, G=0.32 and 0.40) were 
not significantly different and were comparable to other studies (Weaver et al., 1992, 
Buemann et al., 1997, Panarelli et al., 1998 and van Rossum et al., 2002). Even 
though no significant associations between the BclI genotypes and the measures of 
GC sensitivity were found there was a trend for the GG genotype in PTSD to show 
increased responsiveness to DVVA and correlate with the severity of PTSD 
symptoms. In addition, the CAPS score in the GG genotype showed a significant 
negative correlation with basal plasma cortisol levels. Taken together these findings 
are suggestive of increased GC sensitivity in the subset of PTSD possessing the GG 
BclI genotype. As this BclI polymorphism is intronic, its effect on GR gene activity 
may be indirect, such as acting as a marker in a GR function altering mutation. 
Alternatively, it has been suggested that the BclI polymorphism might affect the GR 
gene promoter by selectively acting either on repressor or enhancer sites within the 
promoter thereby altering GC sensitivity (Panarelli et al., 1998). 
 
Recent studies into PTSD have uncovered a number of biological abnormalities 
including a possible dysfunctional HPA axis. A substantial body of studies have 
documented low circulating cortisol levels coupled with evidence of increased 
negative feedback inhibition (Yehuda et al., 1995, Stein et al., 1997, Heim et al., 1998 
and Yehuda et al., 2002) or decreased responsiveness of the adrenal cortex (Kanter et 
al., 2001). However not all studies have confirmed lower cortisol levels in PTSD 
compared to a control group (Halbreich et al., 1989 and Liberzon et al., 1999). At the 
moment it is not clear whether hypocortisolism is a consistent finding in PTSD and if 
it is what role it plays in the development of PTSD. Certainly low cortisols could be a 
general marker of stress system dysregulation and support for this comes from reports 
of hypocortisolism in other stress related disorders such as chronic fatigue syndrome 
and fibromyalgia (Heim et al., 2000). 
 
In this study, patients volunteered from a representative group of well-studied PTSD 
sufferers (Vietnam war veterans), and age matched controls were selected from non-
PTSD affected combat-exposed Vietnam veterans. The PTSD group had been 
diagnosed prior to the study and were participating in therapy/support groups at a 
dedicated psychiatric facility. The severity of the participants' PTSD was assessed 
using CAPS. Other psychiatric diagnoses including active major depression, 
psychosis organic brain syndromes were excluded by a psychiatrist experienced in 
PTSD. Controls were recruited by advertisement and had PTSD excluded by 
interview with a psychologist (TS). The control group were smaller than the patient 
group and neither group was very large, although the study groups were comparable 
to other recent studies of the effect of genetic polymorphisms on psychiatric-
neuroendocrine phenomena (Feng et al., 2000 and Wust et al., 2004). Nevertheless, 
small genotypic effects on the risk of PTSD may have been undetected. 
 
In conclusion, the N363S and BclI GR polymorphisms were not more frequent in 
PTSD patients than controls and reported population frequencies. Our PTSD patient 
group did not display GC hypersensitivity, as measured by the LD-DST and DVVA. 
In a subset of PTSD patients with the BclI GG genotype, CAPS scores and basal 
cortisol levels were negatively correlated. Overall, the results do not support the 
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